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Abstract 
 
We have analysed the natural evolution of transaminase structure and sequence between 
an α-transaminase serine-pyruvate aminotransferase, and an ω-transaminase from 
Chromobacterium violaceum with <20% sequence identity, and identified the active-site 
regions which are least conserved structurally.  We also show that these structural changes 
correlate strongly with transaminase substrate specificity during evolution and therefore 
might normally be presumed to be essential determinants of substrate specificity.  However, 
key residues are often conserved spatially during evolution and yet come from within a 
different region of the sequence via structural reorganisations.  Here we also show that α-
transaminase-type serine-pyruvate aminotransferase activity, can be engineered into the 
CV2025 ω-transaminase scaffold with any one of many possible single point mutations at 
three key positions, without the requirement for significant backbone remodeling, or 
repositioning of the residue from a different region of sequence.  This finding has significant 
implications for enzyme redesign in which solutions to substrate specificity changes may be 
found that are significantly more efficient than by engineering in all sequence and structure 
determinants identified by correlation to substrate specificity 
 
Introduction 
 
Transaminases (EC 2.6.1.) have become increasingly useful industrially and preparatively 
for catalysing the production of chiral amino-moieties including amino-acids, and drug 
molecules such as imagabalin [1], sitagliptin [2], norephedrine and pseudoephedrine [3].  
The Chromobacterium violaceum (CV2025) ω-transaminase was also recently engineered 
into a de novo pathway with transketolase, for the synthesis of chiral amino-diols [4-8]. 
Transaminases are well suited to industrial biotransformations.  They require the pyridoxal 
phosphate (PLP) cofactor, but this is regenerated during the catalytic cycle.  The reaction is 
also fully reversible and typically ends at a thermodynamic equilibrium of K=1, and so amine 
synthesis must be driven to completion for an efficient process.  This can be achieved using 
various reaction engineering methods such as an excess of cheap donor amine, in situ 
product removal using resins or spontaneous coupled reactions, removal of a volatile 
product, or using a coupled enzyme system [9-13]. 
The protein structures of transaminases can be grouped into the type-I folds of PLP-
dependent enzymes comprising the S-selective enzymes, and then also the type-IV folds 
which comprise D-amino acid aminotransferases, L-branched chain amino acid 
aminotransferases, and the R-selective aminotransferases [14-16].  Transaminases are also 
split into six sub-groups in Pfam [17], which broadly mirror their substrate preferences [18].  
Sub-groups I and II contain the α-transaminases (αTAms) and sub-group III contains the ω-
transaminases (ωTAms).  The αTAms catalyse the transfer of amino moieties from the α-
carbon of amino acids to the ketone moiety of an α-ketoacid, whereas the ωTAms mainly 
utilise donors with amines distal to the carboxyl moiety [19, 20], as well as other amine 
donors and their respective non-keto-acid acceptors [21, 22].   
The structures of several type-I fold transaminases have been solved crystallographically, 
including the C. violaceum 2025 ωTAm (CV2025) [23] and S. solfataricus serine:pyruvate 
αTAm (SPAT) [24] which we compare in this study.  Two identical active-sites are positioned 
at the interface between two monomers, with one monomer contributing the majority of the 
substrate binding site.  While the structures of two different ω-transaminases have been 
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compared directly [25], specific differences between the available CV2025 and SPAT 
structures have not been reported in detail previously. 
CV2025 accepts a wide range of amines, notably rac-1-aminoindane, 1-methyl-3-
phenylpropylamine, and (S)-α-methylbenzylamine (MBA) with 183%, 149% and 100% 
relative activity respectively [5].  It also accepts the amino-acid L-α-alanine with 165% 
relative activity to MBA, and yet accepts L-α-serine with only 9% activity relative to that of 
MBA.  Crystal structures for both apo- and holo-enzyme forms of CV2025 were reported 
previously [23].  More recently, a structure of CV2025 bound to the inhibitor gabaculine has 
also been determined through co-crystallisation [25]. This identified a significant 
rearrangement of an active-site loop (residues 81-93), and other residues that interact with 
the inhibitor of potential importance for substrate specificity. 
The S. solfataricus SPAT accepts a range of α-amino-acids [24], in particular methionine, 
phenylalanine and tryptophan.  It also accepts histidine, asparagine, glutamine and serine.  
By contrast, aromatic aminotransferases do not accept serine, hence the classification of the 
SPAT enzyme as a serine:pyruvate TAm (Scheme 1), even though the specific activity with 
serine (0.015 μmol min-1 mg-1, 5 mM substrates) was 4.5-fold lower than for methionine.  
Comparison of the active-site residues of SPAT to those of a distantly related yeast 
alanine:glyoxylate transaminase, suggested that F88 and Y240 in SPAT restricted the 
aromatic substrates to one rotamer, and also sterically excluded threonine [24].  The 
considerably hydrophobic substrate-binding pocket of SPAT was also suggested to explain 
the preference away from charged substrates such as aspartate, glutamate and α-
ketoglutarate.  Finally, a shortened loop between strands 9 and 10 in SPAT moved residue 
V329 further from the PLP and created a larger active-site pocket which potentially favoured 
the larger α-amino-acids. 
Enzyme engineering efforts have been reported for several ωTAm types previously.  For 
example, an ωTAm from Arthrobacter citreus was subjected to error-prone PCR to yield a 
variant, designated CNB05-01, with improved thermostability and 250-fold improved specific 
activity towards a substituted tetralone [26].  Active-site residues within an ωTAm from 
Caulobacter crescentus were identified through structural homology modeling, and then 
targeted by site-directed mutagenesis to investigate their roles in defining or broadening 
substrate specificity [27].  Homology modeling of the Arthrobacter citreus CNB05-01 ωTAm 
variant was similarly used to predict three active-site residues interacting with the aromatic 
group of 4-fluorophenylacetone as modeled to give the R-configuration of the amine [28].  A 
small series of rationally designed mutants yielded some with improved conversion of 4-
fluorophenylacetone, and one which reversed the enantiopreference to an R-selective 
ωTAm for the reaction with isopropylamine and either 4-nitroacetophenone or 4-
fluorophenylacetone.  Homology modeling and substrate docking for ωTAm from Vibrio 
fluvialis also led to the design of two mutants, W57G and W147G, which each altered the 
substrate specificity towards a range of amines [29].  A related W60C mutation in CV2025 
enhanced its specificity towards 4-substituted acetophenones and (S)-MBA [12].  More 
extensive site-directed mutagenesis of the Vibrio fluvialis ωTAm, guided by an analysis of 
homologous sequence alignments, yielded mutants with improved production of an 
intermediate for imagabalin synthesis [1].  Homology modeling and substrate docking were 
also used to guide saturation mutagenesis of active-site residues in the R-selective ωTAm 
ATA-117.  This yielded improved activity towards progressively larger substrates for the 
synthesis of sitagliptin [2].   
The previously reported engineering of TAms have reversed their enantioselectivity or 
modulated their substrate specificity without altering their transaminase subclass.  However, 
the transition between subclasses, such as from an ωTAm to an α-TAm, has not been 
previously explored through directed evolution experiments. 
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Here we have aligned a diverse range of transaminase structures sharing the same type-I 
fold, to highlight significant structural differences between the active sites of αTAms and 
ωTAms, exemplified by SPAT and CV2025 in Figure 1.  A phylogeny analysis of these 
structures has further delineated an evolutionary pathway between the substrate 
preferences of α- and ωTAms, that shifts from α-amino acids, via amines that are 
progressively more distal to the carboxylate moiety, and finally to amines with no carboxylate 
moiety. 
Structural differences between α- and ωTAms were found in regions containing loops that 
form parts of the active site, and include their shortening, lengthening, and remodeling, and 
also the appearance and disappearance of short beta strands and alpha helices.  Given the 
correlation between this extensive restructuring and the evolution of their substrate 
preferences, engineering the interconversion of their substrate specificities to improve αTAm 
type activity within an ωTAm enzyme, might be expected to be very challenging. 
Generally, αTAms are not able to utilize non-amino acid amines, whereas ωTAms have 
evolved to accept them [15].  The ωTAms typically discriminate against amino-acids other 
than alanine or glutamate, formed respectively by aminating their preferred acceptor 
substrates pyruvate and -ketoglutarate.  Thus, engineering an αTAm into an ωTAm is 
potentially a significant challenge given that it must introduce acceptance of a non-
carboxylated amine substrate.  By comparison, engineering an ωTAm to include more 
αTAm-like activity, while retaining or excluding activity on non-carboxylated amines, should 
be a more achievable task.  We therefore set out to test this notion using single-site 
saturation mutagenesis of CV2025 active-site residues, and demonstrated significant 
improvements in SPAT-like L-serine acceptance without also engineering the full SPAT-like 
active-site backbone topology.  Comparison of our variants to sequences along the natural 
evolutionary pathway between the CV2025 and SPAT, has identified key similarities at the 
single residue level, even under a background of significant backbone structure shifts during 
the natural evolution.  This has significant implications for our understanding of the natural 
evolution of enzyme specificities, as well as for improving the available approaches for 
guiding enzyme engineering using sequence comparisons and phylogenetic analyses. 
 
Results and Discussion 
 
Structural alignment and comparison of transaminases 
 
The crystal structures of ω-transaminase from CV2025 and 28 other diversely related 
transaminases, including the serine:pyruvate transaminase from Sulfolobus solfataricus 
(SPAT), were aligned using the DaliLite server [30] to compare their active-site structure and 
topology.  The CV2025 and SPAT structures were also aligned independently using the PLP 
cofactors in Pymol [31], to focus on key structural differences in one active-site forming 
region (Figure 1).  While the two sequences share only 11% identity, their overall secondary 
and tertiary structure topologies are very similar and are clearly evolutionarily related.  
Monomers from each of the two structures aligned for 309 out of 376 SPAT residues to an 
RMSD of 3.4 Å in DaliLite, with most of the deviation originating from regions in their active 
sites. 
 
Overall the SPAT sequence is 75 residues shorter than for CV2025 and there are significant 
deviations in four particular regions (shown in Figure 1 as regions A, B, C and D), around the 
active-site entrances of the two enzymes.  In region A, the first 55 N-terminal residues of 
CV2025 are missing in SPAT, and the following 10-12 loop-residues present within both 
active sites are also significantly remodeled as a result.  The missing 55 residues include 
two short helices within the first 28 amino acids, followed by a three-stranded beta sheet on 
one side of the active-site entrance as shown in Figure 1.  However, the same region is 
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occupied by part of an extended loop and a new 13-residue helix in SPAT from the other 
monomer.  This significantly extends the 11-residue loop (denoted region B) found in 
CV2025 (D314-H325).  Based on a BLAST-P search [32] the first 55 residues of CV2025 are 
not present in 85% of the 226 closest homologues to SPAT. 
 
A relatively smaller structural difference in the active site is in the length of the loop (denoted 
region C) leading from helix 4 (annotation from Humble et al. 2012 [23]) at the surface, 
directly down into the bottom of the active site, and back out again to connect to helix 5, also 
at the surface, thus forming a significant section of the central entrance channel.  CV2025 
accommodates a 13-residue loop (L81-H93), leading to position F88 located deep within the 
central active-site channel, compared to an 8-residue loop in SPAT.  The space created by 
the shorter loop length in SPAT is also filled by part of the extended loop of region B 
described above.  Interestingly, this loop in CV2025 was found to become displaced upon 
binding to the inhibitor gabaculine [25], and the authors suggested that the loop flexibility 
may account for differences in substrate specificity between CV2025 and a closely related 
Pseudomonas ωTAm. 
 
The active-site of CV2025 contains a loop (G152-T157), followed by a single helical turn 
(I158-L163), a 3-residue turn, and finally a second helical turn (K167-G173) which extends 
furthest into the active-site entrance.  Here we denote this as region D.  In SPAT the two 
helices are replaced by a single longer 13-residue helix at the location of the more buried of 
the two CV2025 helices, thus providing a more accessible active-site entrance along with 
the deletion of at least ten interconnecting loop residues found in CV2025. 
 
Other differences reflect the isolation of SPAT from a thermophilic organism, where 
thermophilic enzymes often contain shorter and less flexible loops at the protein surface 
[24].  For example, the C-terminal end of a 19-residue helix present in CV2025 (Y134-P141) 
is missing one helical turn and three subsequent loop residues in SPAT.  The CV2025 helix 
thus protrudes further out into solvent at the enzyme surface than in SPAT, while the 
orientation of the helix relative to the PLP cofactor is significantly altered.  Another surface 
loop containing a single helical turn, plus the first N-terminal turn of a 20-residue helix in 
CV2025 (residues Y189-F200) are also missing in SPAT. 
 
 
Phylogenetic analysis of transaminase structures 
 
The structural alignments of 29 transaminases were used to improve their sequence 
alignment and phylogenetic tree construction, and also provided a subsequent analysis of 
the evolution and structural differences in the active-site regions A, B, C and D as shown in 
Figure 2.  The evolutionary tree shows a clade delineation into α-transaminases (Pfam 
subgroup I) and ω-transaminases (Pfam subgroup III) as expected [18], with the exceptions 
of the glutamine:2-deoxy-scyllo-inosose aminotransferase (PDB ID: 2C81) which groups 
with the αTAms, and the stereo-inverting D-phenylglycine aminotransferase (PDB ID: 2CY8) 
which groups with the ωTAms.  The overall grouping is consistent with the changes in 
sequence identity and RMSD relative to CV2025.  As the sequence identity to CV2025 
increases there is a clear shift from αTAms (subgroup I) which prefer α-amino acids, to 
ωTAms which aminate at ketones positioned further from, or without, a carboxylate moiety 
(subgroup III).  However there is also a progression of the substrate preferences (as 
annotated in the PDB) from beta, through gamma, delta, epsilon and zeta-amines, and 
ultimately on to non-carboxylated amines.  While this range of substrates accepted within 
the ωTAms has been previously reported [18], the evolutionary progression above has not 
been previously resolved. 
 
 6 
Figure 2 also shows that the RMSD for structures aligned to that of CV2025 shifts smoothly 
from below 3 Å in ωTAms to above 3 Å in αTAms, concurrent with a gradual sequence 
identity drop to below 13% to that of CV2025.  Visual comparison of all structure alignments 
allowed us to identify clusters of structure types that were similar in regions A, B, and D.  
These clusters were found to map directly onto each clade within the phylogenetic tree as 
shown in Figure 2, demonstrating a clear link between the remodeling of each active site 
region and the substrate specificity of each enzyme subgroup.  By contrast, the length of the 
loop denoted region C does not cluster with transaminase type, but rather varies 
considerably across all transaminases, with a difference of up to 10 residues from the 
shortest to the longest, and no clear trend. 
 
With such significant differences between the active sites of ωTAms and αTAms, we set out 
to determine whether SPAT-like activity could still be engineered into the CV2025 scaffold 
using only single active-site mutations, and without remodeling of regions A, B, C and D 
towards a SPAT-like active-site topology.  The grouping of glutamine:2-deoxy-scyllo-inosose 
aminotransferase (PDB ID: 2C81) with the αTAms indicates that the αTAm active site 
architecture can accommodate ωTAm-type activity.  However, ability to engineer an 
interconversion between the two enzyme classes in the opposite direction, and with only 
single mutations, is not yet known. 
 
 
Selection of target residues 
 
Two computational structure modeling approaches were combined to select CV2025 ωTAm 
active-site residues with the potential to influence specificity through direct interaction with 
substrates.  The active-site cavities were first mapped using CAVER [33] on the holo-
enzyme in which pyridoxal-phosphate (PLP) forms a Schiff's base to K288.  This mapped 
the large and small substrate-binding pockets in addition to the central channel leading out 
of the active site, and defined the region of structure in which to confine substrate docking by 
AutoDock [34].  Six substrates known to be either well (pyruvate, alanine, 
methylbenzylamine, acetophenone), or poorly (serine and hydroxypyruvate) accepted by 
CV2025 [5] were docked into the active-site, and the major clusters of final poses were used 
to identify all nearby residues with the potential to contribute to their binding, and thus 
provided targets for saturation mutagenesis.  Details of the contacts made with each 
substrate and residue are provided in the supplementary information (Table S1).  The 
selected residues are shown in Figure 3 along with the final docked positions for each 
substrate. 
A total of 11 residues were selected for site-saturation mutagenesis (P21, F22, L59, W60, 
F88, Y153, A231, G319, F320, T321, R416), that were predicted to interact with at least one 
of the substrates.  Three additional residues were selected due to their close proximity to the 
PLP cofactor (Y322), or their potential to create large cavities at the active-site entrance 
upon mutation (F89, Y168).  All but one of these residues are highly conserved among 100 
sequences with at least 40% sequence identity to CV2025, as summarised in Table 1.  Four 
target residues, L59, Y153, G319 and T321 are completely conserved (H(x)=0).  Only Y168 
is highly variable (H(x)>2.0).  The amino acid found at each equivalent position in SPAT is 
also shown in Table 1.  These are different to any of the residues found in ωTAms, with four 
exceptions.  F88 in CV2025 is F in SPAT and also in 90% of related ωTAms.  F89 in 
CV2025 is S in SPAT and also in 10% of related ωTAms.  A231 in CV2025 is S in SPAT and 
also in 3% of ωTAms.  F320 in CV2025 is F in SPAT and also in 38% of ωTAms.  The 
active-site residues in CV2025 therefore appear to be highly specialised toward ωTAm 
activity, and have little similarity to those found in SPAT. 
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Library generation and high-throughput screening 
Saturation mutagenesis with the NNK codon was targeted to each of the fourteen residues 
independently, and 76 colonies randomly picked into 96-well plates, along with controls, as 
the basis for each residue library.  Enzyme variants were expressed in E. coli 
BL21(DE3):pQR801 using IPTG induction, as described in Materials and Methods.  DNA 
sequencing from random wells demonstrated that a wide diversity of mutations had been 
created in each library.  A high-throughput colorimetric screen was used to assess the total 
enzyme activity from the conversion of serine and pyruvate to hydroxypyruvate and alanine 
after 3 hours, for each variant prepared as a crude lysate. The hydroxypyruvate generated 
was detected by reaction with WST-1 tetrazolium salt, giving rise to a blue coloration due to 
reduction of the tetrazolium and oxidation of the hydroxypyruvate.  Complete sequencing of 
the Y153X library revealed a bias of 30% wild-type colonies, but a random distribution of 
between 0 and 7 occurrences for all other mutations, with all but five amino-acids (I,D,H,Q,T) 
represented.  The expected number of distinct variants from the remaining 70% of 76 
colonies, calculated using GLUE-IT [35], is 17.  Sequencing of the 13 highest performing 
(non wild-type) W60X colonies revealed 6 of the 19 possible substitutions.   
The maximum activities obtained within each library are shown in Figure 4.  Transaminase 
expression levels in clarified lysates were also determined by SDS-PAGE with densitometry 
and found to vary only slightly in all of those measured, from 0.25-0.41 mg/ml (0.1 mg/ml).  
Positions Y153, W60, F88 and T321 gave mutants with up to 4-fold, 4-fold, 3-fold and 2-fold 
improvements, respectively, in total activities towards 10 mM serine, 10 mM pyruvate at pH 
7.0.  Position L59 gave a modest 1.4-fold improvement, while all other residues led to no 
improvement in activity above that of wild type, even though a range of mutants were always 
identified within the libraries by random DNA sequencing.  It is notable that five of the seven 
most highly conserved (H(x)≤0.4) residues among ωTAms could be mutated to give variants 
with improved SPAT-like activity, whereas all of the lesser conserved residues yielded no 
better than the activity of wild-type CV2025.  This is consistent with our previous analysis of 
saturation mutagenesis of enzymes for improved activity or substrate specificity, and other 
examples [36-38], where the most effective mutations were found at highly conserved 
residues in direct contact with substrates or cofactors.  It is anticipated that such residues 
are those that most strongly define enzyme substrate specificity, and are therefore precisely 
those that must be altered to allow the improved acceptance of new substrates. 
For ωTAm, all of the mutants with at least 2-fold improved total activity towards serine were 
obtained at residues with H(x) values of 0.4 or below.  If this had been used as a cut-off 
criterion for choosing target residues, the same mutants could have been obtained by 
creating and screening only half of the libraries.  This echoes our previous work on 
transketolase where an H(x) value of 0.4 or below would have found all mutants that altered 
substrate specificity, and decreased the target residues from twenty to only nine [37, 39].  
However, using this cut-off value of H(x) alone can come with some case-specific knock-on 
effects.  For example, saturation mutagenesis of T. litoralis aminoacylase residues with H(x) 
values below 0.3, did give the greatest substrate specificity changes, but they also resulted 
in a partial decrease in the overall catalytic efficiency [38]. 
The distribution of mutations tolerated at the top-three sites provides further insight into the 
functional importance of each residue for maintaining the substrate specificity of ωTAm, and 
also the overall catalytic efficiency.  The averaged activities for all sequenced mutants within 
the Y153X, W60X and F88X libraries are shown in Figure 5.  Strikingly, serine:pyruvate 
activity was highly tolerant to many different types of mutation at these three sites. 
Position Y153, yielded ten mutants with between 2-fold and 4-fold improvements over the 
wild-type activity.  Two more (Y153E and Y153K) retained 50% activity, while only two 
(Y153R and Y153P), completely abolished activity.  This is in stark contrast to the 100% 
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conservation of this residue in the ωTAms related to CV2025, although Phe is often 
observed at this position in the more distantly related ωTAms.  The equivalent residue in 
SPAT is also Phe, and the Y153F mutation in CV2025 gave 3.5-fold improved SPAT activity.  
However Y153M, Y153N and Y153S each gave 4-fold improvements, indicating that simple 
mutation of CV2025 towards the residues present in SPAT, while a successful strategy, will 
not necessarily provide the best possible activities.  During the review of this paper, the 
equivalent mutations to Y153F and Y153M in V. fluvialis ωTAm have been identified 
independently, and were found to decrease the specific activity towards methylbenzylamine, 
yet increase it towards (R)-phenylglycinol [40]. 
The hydroxyl group of Y153 hydrogen bonds via water to the phosphate moiety of PLP [41], 
positioning Y153 across the active site and directly above the PLP cofactor, potentially 
acting as a gateway residue for substrate access.  Mutations towards charged residues (E, 
K, R) are all detrimental to activity, implying an electrostatic destabilisation of PLP binding 
into a functional position.  Humble et al previously observed that Y153K decreased the 
enzyme activity, and attributed this to the loss of the edge-on interaction of the Y153 phenyl 
ring with the pyridine ring of PLP, as well as loss of the hydrogen bond via water to the 
phosphate moiety of PLP.  However, mutations to almost any other residue than charged 
variants, and notably Y153F, remove the hydrogen bond interaction yet lead to increased 
activity towards serine.  The magnitude of this increase does not appear to be related to the 
size of the new residue side-chain, indicating that steric hindrance is no longer a major factor 
for serine access to the PLP cofactor once the hydrogen bond is removed.  Proline, which 
abolishes activity completely, presumably is structurally destabilising to the active site. 
Position W60 was also very tolerant to substitution, with six mutations (W60Q, W60S, 
W60H, W60T, W60N and W60P), giving between 2-fold and 3.5-fold improvements in 
activity.  The equivalent residue in SPAT is G9, yet mutation to Gly was not observed.  Close 
relatives to CV2025 often contain a Tyr (2%) or Phe (10%) at this position, but none of these 
were observed under serine:pyruvate screening conditions.  More distantly related ωTAms 
identified in the structure alignments, such as ornithine-AT (PDB ID: 1OAT), 4-
aminobutyrate-AT  (PDB ID: 3OKS and 1SFF), acetylornithine-AT (PDB ID: 2ORD), L-lysine-
epsilon-AT (PDB ID: 2CJG), beta-phenylalanine-AT (PDB ID: 4AO9), and D-phenylglycine-
AT  (PDB ID: 2CY8), contain Ser, Ala, Thr or Gly at equivalent sites.  These enzymes are all 
evolutionarily mid-way between SPAT and CV2025 (Figure 2) in both sequence and 
structure, and they also aminate ketones that are distal to a carboxylate moiety (with the 
exception of D-phenylglycine-AT).  However, they are clearly clustered evolutionarily with 
the ωTAms.  The identification also of W60S and W60T mutations with greater SPAT-like 
activity, and the presence of Ser and Thr in natural ωTAms which accept amino-acids with 
more distal amines, suggests the possible role of the W60 mutations in controlling the 
tolerance of a carboxylate moiety in the amine acceptor substrate.  Interestingly, an 
equivalent mutation (W57G) in Vibrio fluvialis ωTAm, which has a preference for aromatic 
amines, was found to improve the acceptance of aliphatic amines [29].  Furthermore, the 
W60C mutation in CV2025 has been previously shown to improve kcat/Km for 4’-substituted 
acetophenones and (S)-MBA [12].  This alternatively suggests that our mutations of W60 to 
smaller residues may also be providing generally increased steric access and activities, 
including serine. 
Residue F88 was similarly very tolerant to substitution, such that six mutants (F88R, F88H, 
F88Q, F88S, F88T, F88I), gave between 3-fold and 2-fold improvements in activity.  Again, 
the only natural variation at this position within the close relatives of CV2025 was Tyr (10%), 
which was not observed when screening for SPAT-like activity.  Within more distantly related 
ωTAms, the equivalent residue can be Met, Leu, Gly, Arg, Ala, Asn, Gln, or Ser, and three of 
these were found in the top four F88 mutations (F88R, F88Q and F88S).  At this position, 
Arg, Gln and Ser are found respectively in ornithine-AT (PDB ID: 1OAT and 1GBN), 4-
aminobutyrate-AT (PDB ID: 1SFF but not 3OKS), and L-lysine-epsilon-AT (PDB ID: 2CJG).  
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As previously with the W60 mutations, the phylogenetic analysis of natural TAms infers that 
F88R, F88Q and F88S mutations might better accommodate the carboxylate moiety within 
the amine acceptor substrate.  Hence, these same mutations could provide improved affinity 
to serine through the same mechanism.  The selection of positively charged (Arg) or polar 
hydrogen bonding (Gln, Ser) residues at F88 is consistent with an interaction with a 
carboxylate.  However, in SPAT and in many other αTAms the F88-containing structure 
(Region C) is distinctly different due to a widely varying loop length as described above, and 
so no fully equivalent residue to F88 exists.  Instead, SPAT contains a shorter loop in region 
C, leading to a partially equivalent residue F28 in region C of SPAT (Figure 1B).  An 
extended loop in region B of SPAT also partially replaces F88 in CV2025 with SPAT residue 
Y240.  The net result is a small cavity in SPAT that is filled by the aromatic ring of F88 in 
CV2025. 
The binding of gabaculine to the holo-CV2025 enzyme in a co-crystal structure significantly 
alters the region B loop (residues 81-93) resulting in F88 pointing out of the active site [25].  
It is therefore also plausible that some F88 mutations could have disrupted the loop in the 
holo-CV2025 form, improving access to the active site by pre-forming this putative substrate 
binding conformation. 
Other residues also displayed interesting behaviour in terms of tolerance to mutation.  For 
example, L59 gave a 1.4-fold improvement with L59M, but no other mutants were identified 
at this residue with greater than wild-type activity.  The equivalent residue in SPAT is V8, 
and other ωTAm structures contain Trp, Ile, or Tyr at the equivalent site, but not Met.  
Residue T321 tolerated mutations to Ala and Ser with no loss in activity, and mutations to 
Gly and Lys with 50% of the activity retained.  However, T321R abolished activity 
completely.  The equivalent residue in SPAT is A242.  Similarly, F89 tolerated mutation to 
Leu without loss in activity, whereas substitutions to Glu, Pro and Ser each resulted in 15-
20% retention of activity.  The equivalent residue in SPAT is S30.  A Glu at the equivalent 
position is also found in diaminopelargonic acid aminotransferase, an ωTAm distantly 
related to CV2025.  Residue F22 retained wild-type levels of activity from mutations to Trp 
and Met.  There is no equivalent residue in SPAT.  Y322 also tolerated substitutions to Cys, 
Leu, Thr, Ser and Phe with between 10% and 35% retention of activity.  The equivalent 
residue in SPAT is T243.  F320 gave mutations to Cys and Ser with 30% and 50% retained 
activity.  The equivalent residue in SPAT is F241.  A231 was mutated to Thr with 70% 
activity retained. Threonine is found in 9% of ωTAms closely related to CV2025.  The 
equivalent residue in SPAT is S139, which is also similar to threonine. 
By contrast, only residue R416 appeared to be intolerant to mutation.  Fourteen colonies in 
total for R416X were sequenced, including all of those that were active.  All active colonies 
were wild-type transformants, and all other randomly identified mutants R416Q, R416L and 
R416S resulted in completely abolished activity.  The equivalent residue in SPAT is A326.  It 
is possible that the two naturally observed ωTAm variants of His (8%) and Thr (1%), and the 
SPAT equivalent of Ala at this position were simply not generated in the library, or otherwise 
that they are not active towards serine:pyruvate. 
To summarise, nine libraries were generated at positions for which there is a clear 
equivalent residue in SPAT (excluding CV2025:F88).  The amino-acid found at each site in 
SPAT was identified in five libraries: one (Y153F) with improved SPAT activity, and four 
(F89, F320, T321, Y322) where they tolerated the mutation with no improvement in SPAT-
like activity above that of wild-type CV2025.  One other residue (A231) tolerated a threonine 
mutation, which is homologous to the serine found in SPAT.  This demonstrates that 
mutation towards the equivalent residues in SPAT can be successful for gaining SPAT-like 
substrate specificity, even though the active-site structure in regions A-D around the mutated 
residues, differ significantly between the two wild-type enzymes.  Therefore, the CV2025 
structural form of regions A-D does not preclude SPAT activity. 
 10 
Three libraries (W60X, F88X, Y153X) yielded improved SPAT-like activity, from mutations 
that also occurred at equivalent positions in the ωTAms found on the evolutionary path 
between CV2025 and SPAT.  Another four (F89X, A231X, F320X, T321X) libraries tolerated 
such mutations with 15-100% retained activity.  This finding demonstrates that a more 
SPAT-like preference for serine can already emerge through single active-site mutations 
found in variants only part way along the evolutionary path to SPAT.  Improved activity with 
serine involves a shift from acceptance of non-carboxylated amines to a carboxylated amine, 
which reflects a similar shift along the natural evolutionary path from non-carboxylated 
amines in CV2025, through (β/γ/δ/ε/ζ)-amines (relative to the carboxylate moieties) in other 
ωTAm variants, and finally to α-amino acids in SPAT and other αTAms. 
 
Kinetic analysis of purified Y153 mutants 
Two mutants, Y153M and Y153S, which performed best in the high-throughput screen, were 
chosen for detailed kinetic analysis along with the wild-type enzyme, to compare the 
acceptance of serine to that of two substrates rac-aminoindane and (S)-MBA preferred by 
wild-type CV2025.  Neither of the two mutations were observed in SPAT, or any of the TAm 
structures, or from the BLASTP sequences closely related to CV2025.  Therefore, it was 
interesting to understand them further in terms of their kinetic effects.  The mutant enzymes 
were purified and characterised at a range of serine, rac-aminoindane or (S)-MBA 
concentrations and a constant pyruvate concentration.  Pyruvate concentration was fixed at 
10 mM to avoid substrate inhibition observed at higher concentrations.   
The initial velocity enhancements, expected in the high-throughput screen with serine, can 
be calculated from the kinetic parameters at 10 mM substrates shown in Table 2.  This gives 
21.7-fold and 5.3-fold improvements for Y153M and Y153S respectively, which are higher 
than the 4-fold activity improvements observed by high-throughput screening.  This 
difference simply results from the non-linear relationship between initial velocities, and the 
degree of conversion at a fixed time-point used for high-throughput screening. It does not 
result from any differences in expression level for the clarified lysates used in the screening.  
Therefore the improvements shown in Figures 4 and 5 give the correct relative order of 
mutant activities, and the same conclusions discussed above, but the enhancements in 
activity relative to wild-type should actually stretch to up to 22-fold for the fastest (Y153M). 
The kcat of wild-type CV2025 enzyme towards aminoindane and MBA were each 16-fold 
higher than that for serine (0.5 s-1).  Meanwhile, the Km for serine (260 mM) was 17-fold and 
9-fold higher respectively than those for aminoindane and MBA.  These results are 
consistent with the specific activities previously reported for CV2025 [5].  The Y153M 
mutation had little effect on kcat for the three substrates.  However, the Km decreased 1.5-fold 
for aminoindane and 2.5-fold for MBA.  By contrast, the Y153M mutation led to a 57-fold 
improvement in Km for L-serine.  The overall improvement in kcat/Km for Y153M relative to 
wild type was 67(±12)-fold for serine, but only 1.5-fold for aminoindane and 2.5-fold for MBA, 
indicating a strong shift in substrate preference towards serine relative to the tωο non-
carboxylated amines. 
The Y153S mutation led to a small (1.2-fold) decrease in kcat for serine.  This loss was more 
than countered by a 20-fold decrease in Km for serine.  By contrast, kcat decreased 160-fold 
and 7-fold for aminoindane and MBA respectively, but Km decreased by only 34-fold and 3-
fold respectively.  The net result was again a significant shift in substrate preference towards 
serine relative to the tωο amines, such that kcat/Km improved 16(±3)-fold for serine, but 
decreased 4.5-fold and 2-fold for aminoindane and MBA respectively. 
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The effect of the Y153M and Y153S mutations occurs mainly via Km, showing a clear impact 
on substrate affinity by the mutations. The CV2025 transaminase active-site thus shows a 
high plasticity in its ability to significantly alter substrate specificity with just single mutations.  
The two mutants Y153S and Y153M both remain as -transaminases with kcat/Km values for 
aminoindane and MBA at 4 to 6.5-fold higher, than for serine.  However, this has closed the 
gap considerably compared to the wild-type CV2025 for which kcat/Km for aminoindane and 
MBA was 290-fold and 147-fold higher than for serine.  Thus the Y153S and Y153M 
mutations have largely removed the discrimination against serine observed in the wild-type 
CV2025, while also retaining catalytic efficiency, particularly in Y153M.  Only Y153S shows 
any impact on catalytic efficiency, with a minor decrease for serine but more significant 
decreases for aminoindane and MBA.   
The specific activity of SPAT at 5 mM serine and 5 mM pyruvate is 0.015 μmol mg-1 min-1 
[24], which is 50% higher than that calculated for CV2025 (0.01 μmol mg-1 min-1) from the 
kinetic parameters under similar conditions.  By this measure, CV2025 is already a 
reasonable acceptor of serine relative to SPAT.  The specific activities of the two new 
CV2025 mutants Y153S and Y153M are similarly calculated from the kinetic parameters at 
5 mM substrates to be 0.13 μmol mg-1 min-1  and 0.36 μmol mg-1 min-1, respectively.  Clearly 
then, the mutant CV2025 enzymes both have significantly higher SPAT activity than the 
SPAT from S. solfataricus.   
 
Conclusion 
Analysis of the natural evolutionary pathway between SPAT and CV2025 has revealed a 
gradual progression from the acceptance of α-amino acids, through amines that are 
increasingly distal to the carboxylate moiety, and finally to a preference for non-carboxylated 
amine substrates in CV2025.  This pathway correlates with significant structural shifts in 
regions A-D within the enzyme active-site.  Surprisingly, up to a 67-fold improvement in 
kcat/Km could be elicited towards SPAT activity from a single mutation, while 3-4 fold 
increases in SPAT activity could also be obtained from a wide range of different substitutions 
at any one of three key residues.  The kcat/Km values for the favoured ωTAm substrates, 
aminoindane and MBA, were also improved in Y153M but decreased in Y153S.  This 
showed how saturation mutagenesis of single residues is sufficient to significantly modulate 
the substrate specificity of the ωTAm CV2025 to include that of SPAT from the αTAm 
subclass.  However, the extensive active-site structure and sequence differences, found to 
correlate to subclass specificities, may yet still be required to engineer these new mutants 
for the complete discrimination against non-amino acid amines.  Our results also indicate 
that Y153, W60 and F88 in CV2025 are all important positions for defining ωTAm substrate 
specificity.  Y153 appears to be a key gateway residue which controls access to the PLP 
cofactor, and which can be opened up to allow serine access through almost any mutation 
except charged variants and proline.  Some of the most highly conserved active-site 
positions in CV2025, including Y153, W60, F88 and T321, were highly tolerant to many 
alternative mutations when screening for SPAT activity, demonstrating the high plasticity of 
the transaminase active site, and also suggesting that ω-TAm substrate specificity is partly 
driven by conserving the exclusion of α-amino acids. 
The mutants found were often similar to those found at equivalent positions in sequence, or 
at least in structural space, along the natural evolutionary pathway between the CV2025 and 
SPAT.  This is consistent with the important role and conservation of particular active-site 
residues spatially within the active site.  It also suggests that the extensive structural 
remodeling, observed as distinct transaminase sub-classes have evolved, are not critical for 
conserving one particular substrate preference.  It is thus tempting to conclude that single-
site saturation mutagenesis provided a more efficient route to SPAT activity than by 
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mimicking the natural evolutionary pathway.  However, the larger structural differences in 
active-site regions A-D between SPAT and CV2025 may conserve additional aspects such 
as the wider profile of their substrate preferences, feedback regulation/inhibition behaviours, 
or even fine-tune their relative catalytic proficiencies (kcat) to levels which optimise flux 
through their respective metabolic pathways. 
Finally, our engineered CV2025 ωTAm variant with improved activity towards serine, also 
generates hydroxypyruvate (HPA) as a byproduct. This has potential use in reactions 
coupled after transketolase (TK) which also accepts HPA, similar to a synthetic scheme 
demonstrated for the synthesis of 6-deoxy-L-sorbose [42].  This could now be applied within 
our de novo TK-TAm pathways [4, 8] to remove the need for HPA addition. 
Materials and methods 
Except where stated, all reagents were obtained from Sigma–Aldrich (Gillingham,UK) and 
used without further purification. 
 
Structural alignment of transaminases 
A similarity search within the protein databank webserver [43] was used to identify 28 TAms 
that are structurally related to that of Chromobacterium violaceum ω-Transaminase (CV2025 
ωTAm) in the holo form (PDB ID: 4A6U) [23].  The structures included the serine:pyruvate 
transaminase from Sulfolobus solfataricus (SPAT) (PDB ID: 3ZRP) [24], along with a diverse 
range from high to very low sequence identity.  From over 200 initial structures, those with 
unknown or non-TAm functions were removed.  Near-identical structures and their mutants 
were also removed.  The 28 structures remaining were aligned to the CV2025 chain A 
monomer using the DaliLite server [30], to compare their active-site structure and topology, 
and to obtain RMSD data.  RMSD data reported are for alignments of the monomeric 
structures alone, and typically aligned 300-451 residues.  These structure alignments were 
also used to generate sequence alignments, which were then refined manually using the 
visualised structures as guidance, particularly in active site regions, to obtain accurate 
sequence identity values as well as a reliable table of amino acid substitutions at key active-
site residues.  This refinement was particularly necessary for structure pairs with higher 
RMSD values. 
 
Phylogenetic analysis of the transaminase structure-sequence alignment 
The 29 aligned sequences from the TAm structures were used to obtain a Maximum 
Likelihood tree phylogeny with the PHYLIP package program ProML [44].  Neighbour-joining 
(NJ) tree phylogenies were also obtained using Protdist via BioEdit [45] for comparison.  
Identical results were obtained with each method, and the NJ tree was retained. 
 
Multiple sequence alignments for CV2025 and SPAT 
 
Multiple protein sequence alignments were obtained with compositional matrix adjusted 
identities of >40% using sequence searches from NCBI-BLASTP [32] and both CV2025 
TAm and SPAT as the query sequences, and multiple sequence alignment with ClustalX 
and the BLOSUM62 alignment matrix [46].  The initial BLASTP searches were set to yield 
1000 and 500 sequences related to CV2025 and SPAT, respectively.  Only one sequence 
from any single species was accepted, taking the one with the lowest sequence identity to 
maximise diversity, giving 100 and 226 final sequences related to CV2025 and SPAT, 
respectively, for the multiple sequence alignment.  Each alignment was manually improved 
by eye in BioEdit. 
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In-silico active site mapping 
Cavities within the CV2025 TAm structure and the immediately surrounding residues were 
mapped using CAVER [33] and default parameters, with the crystal structure of the enzyme 
in the holo form with PLP forming a Schiff's base to K288 (PDB ID: 4AH3, provided in 
advance by personal communication with Prof Jennifer Littlechild) [25].  The same sites 
were reconfirmed using another published structure (PDB ID: 4A6U) [23].  Surrounding 
residues were then identified by visual inspection of the structure overlaid with the 
highlighted cavities in Pymol [31].  Active-site residues that could potentially contact 
substrates were identified by independently docking MBA, acetophenone, serine, pyruvate, 
alanine and hydroxypyruvate into the CV2025 TAm structure, using AutoDock software 
version 4.0 [34].  Substrate docking models were obtained in the active site, using a cubic 
grid centred at (-24.896 -17.433 -48.359) with sides of 80 Å to cover the active-site cavities 
identified above.  Defaults were used for docking each substrate except for the following: the 
maximum number of energy evaluations was increased to 1 million, the number of genetic 
algorithm (GA) runs was increased from 10 to 200, and the grid spacing used was 0.375 Å.  
Cluster analysis by AutoDock on each final conformation obtained from the 200 GA runs 
grouped those with an RMSD of less than 0.5 Å.  Clusters were then ranked in order of 
increasing energy.  Visual analysis of docked conformations was carried out in Pymol.  All 
amino acids found to interact with at least one substrate were selected for saturation 
mutagenesis. 
 
Sequence conservation and entropy 
Protein sequence conservation at each site in CV2025 TAm was determined from the 
multiple protein sequence alignment of 100 sequences with compositional matrix adjusted 
identities of >40%.  Excess sequence beyond the N and C-terminal ends of the CV2025 
query sequence, or gaps within CV2025 sequence, were deleted.  Sequence entropy, H(x), 
was calculated at each site using BioEdit, where the maximum entropy for 21 possible 
amino acids (including stop codon) is 3.04 and zero represents a fully conserved residue. 
 
Saturation mutagenesis and screening of ω-Transaminase mutants 
CV2025 ω-Transaminase was expressed throughout upon IPTG induction, from plasmid 
pQR801 [5] transformed into E. coli BL21(DE3) (Stratagene, Netherlands).  Saturation site-
directed mutagenesis was performed using Quikchange kit (Stratagene, Netherlands) 
according to the manufacturers instructions, and mutated plasmids retransformed into 
chemically competent E. coli BL21(DE3) cells.  Saturation mutagenesis primers used, along 
with their reverse complement sequences, were as follows: 
 
P21 CCATCACCTGCATNNKTTCACCGATACC 
F22 CCGNNKACCGATACCGCATCGCTGAACC 
L59 CGACGGCATGGCCGGANNKTGGTGCGTGAACGTCG 
W60 GGCATGGCCGGACTGNNKTGCGTGAACGTCGG 
F88 CCGTTCTACAACACCNNKTTCAAGACCACC 
F89 CTACAACACCTTCNNKAAGACCACCCATCC 
Y153 GCTGGAACGGCNNKCACGGCTCC 
Y168 GCATGAAGNNKATGCACGAGCAGG 
A231 GCGAACCCATCCAGGGCNNKGGCGGCGTGATCGTCC 
G319 CGACTTCAACCACNNKTTCACCTACTCC 
F320 CGACTTCAACCACGGCNNKACCTACTCC 
T321 CGACTTCAACCACGGCTTCNNKTACTCCGGCCACCCGGT 
Y322 CGACTTCAACCACGGCTTCACCNNKTCCGGCCACCCGGT 
R416 CCTGATCATGNNKGCATGCGGCGACC 
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For each library 76 colonies were picked and inoculated into wells of a 96 deep-square well 
(DSW) plate containing 900 µl of terrific broth (TB) with 100 g/ml kanamycin.  Each 96-well 
plate contained twelve negative control wells of media only, and eight wells with E. coli 
BL21(DE3):pQR801 expressing wild-type CV2025 ω-Transaminase, of which four each 
were used as reaction positive and negative controls respectively.  Microplates were 
covered with an inverted DSW plate, sealed, and incubated at 37 °C, 300 rpm, 50mm orbital 
throw, 85% humidity for 16 hours to stationary phase in an incubated shaker (INFORS HT 
Multitron, Bottmingen Switzerland).  Liquid handling was performed with a Genesis robot 
(Tecan, Reading, UK) to minimise errors.  From each well, 100 µl culture was inoculated into 
fresh 900 µl terrific broth with 100 g/ml kanamycin, grown to OD600 2.0 under the same 
conditions, then induced with 0.89 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG), and 
the temperature decreased to 32 °C for 5 hours.  Cells were harvested by plate 
centrifugation at 4300 rpm (3102g) for 15 minutes, the medium discarded and cells 
resuspended in 1 ml 0.1 M potassium phosphate, pH 7.0, 0.2 mM pyridoxal phosphate 
(PLP), by shaking for 10 min at 37 °C, 300 rpm, 50 mm orbital throw, 85% humidity. 
Centrifugation and resuspension was repeated once, then the plates frozen and stored at -
80 °C for up to 6 months.  At least six randomly picked colonies from each residue library 
were sequenced to assess the diversity of the libraries. In addition, the top performing 
colonies from each library were sequenced, even if the activity did not improve above wild-
type.  Finally, the Y153X library was sequenced completely. 
 
Reaction plates were created by transferring 30 µl of each thawed cell suspension into 
standard 96-well plates containing 225 µl lysis buffer (0.2 mg/ml lysozyme, 0.2 mM PLP, 
0.1 M potassium phosphate pH 7.0, 10% bug buster (Life Technologies, Paisley, UK).  Cells 
were resuspended for 10 minutes in a Thermomixer Comfort microshaker (Eppendorf, 
Hauppauge, NY) at 21 °C, 1000 rpm, 3 mm orbital throw, then 30 minutes at 37 °C, 300 rpm, 
50 mm orbital throw, 85% humidity. Lysed cells were centrifuged for 60 minutes at 4300 rpm 
(3102 g) at 4 °C then 55 µl of the clarified lysate transferred into standard 96-well plates, 
stored at 4 °C, and used for reaction screens within 6 hours. Expression levels within 
clarified lysates were assessed by SDS-PAGE and densitometry. Reaction plates were 
equilibrated to 37 °C, and enzyme assays initiated by adding 145 µl 0.1 M potassium 
phosphate, pH 7.0, 0.2 mM PLP, and 13.8 mM substrates to give 0.2 mM PLP, 10 mM 
serine and 10 mM of pyruvate.  Reaction plates were sealed and shaken at 37 °C, for 3 
hours at 50 rpm, then 10 µl transferred to another plate containing 190 µl of 0.125 mM WST-
1 tetrazolium salt dissolved in 0.11 M NaOH, shaken at 50 rpm for 10 minutes and the 
absorbance at 595 nm measured in a platereader.  Reaction with the hydroxypyruvate 
product leads to an increase in blue colour. 
Enzyme mutant purification and detailed kinetic analysis 
Wild-type enzyme and two promising mutants Y153M and Y153S were overexpressed and 
purified using Sepharose fast flow Ni-NTA resin (GE Healthcare, Little Chalfont, UK). Eluted 
samples were buffer exchanged using PD-10 desalting columns (GE Healthcare, Little 
Chalfont, UK) into 0.1 M potassium phosphate, pH 7.0, 0.2 mM PLP.  Serine/pyruvate 
reactions were performed in triplicate with 10 mM pyruvate, and 5-200 mM L-serine, using 
0.3 mg ml-1 wild-type enzyme or 0.03 mg ml–1 mutant enzymes at 37 °C.  The 
hydroxypyruvate product was determined by sampling at regular intervals with an Aminex 
HPX-87H ion exchange HPLC column (300 mm x 7.8 mm; Bio-Rad, Hemel Hempstead, UK) 
as described previously [5]. Reactions with (S)-MBA or aminoindane were performed with 
10 mM pyruvate, and 0.15-50 mM (S)-MBA or racemic aminoindane, using 0.4 mg ml-1 
enzyme at 37 °C. Formation of acetophenone from MBA or 1-indanone from aminoindane 
was followed by RP-HPLC using an ACE 5 C18 reverse phase column (150 mm × 4.6 mm, 
5 μm particle size; Hichrom Limited, Berkshire, UK). A gradient was run from 15% 
acetonitrile / 85% 0.1% (v/v) trifluoroacetic acid (TFA) to 72% acetonitrile / 28% TFA over 
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8 min, followed by a re-equilibration step for 2 min (oven temperature 30 °C, flow rate 
1 mL/min). UV detection was carried out at 250 nm. No substrate inhibition was apparent.  
Kinetic parameters were obtained by fitting to the standard Michaelis-Menten equation by 
linear regression. 
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Supplementary Information 
 
  Substrate 
ChainA ChainB HPA MBA Acetophenone Serine Pyr1 Pyr2 Alanine 
P21   HF      
F22     HF HF         
L59  HF HF HF HF    
W60       HF     PiP   
 F88  HF      
Y153     HB/HF HF/N HF/N     PiP 
Y168      PiP   
A231   HF HF HF HF       
 G319  HF HF/N     
  F320   HF           
 T321 HB/N HF/N HF HF/N    
R416   N   HF HB N  N 
 
Table S1.  
Interactions of computationally docked substrates with active-site residues.  
        Interactions denoted are: (N) with amino acid backbone nitrogen; (HF) hydrophobic; 
(HB) hydrogen bond; (PiP) polar-pi interaction. All substrates docked into a single 
cluster with the lowest binding energy, with the exception of pyruvate which clustered 
into two major groups denoted Pyr1 and Pyr2. 
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Tables 
  
 
Residue H(x) Amino-acid frequency (%) Residue 
  A  F   G  H   L   N  P  R  S   T   W   Y   ~  in SPAT
 a 
P 21 0.7 6 0 1 0 0 0 81 0 10 0 0 0 2 - 
F 22 1.1 0 64 1 0 1 0 0 0 9 0 0 20 2 - 
L 59 0.0 0 0 0 0 100 0 0 0 0 0 0 0 0 V8 
W 60 0.4 0 2 0 0 0 0 0 0 0 0 88 10 0 G9 
F 88 0.3 0 90 0 0 0 0 0 0 0 0 0 10 0 F28 
F 89 1.1 5 69 2 0 0 1 0 0 10 6 0 0 0 S30 
Y 153 0.0 0 0 0 0 0 0 0 0 0 0 0 100 0 F88 
Y 168 2.1 13 10 27 3 0 13 3 0 6 0 1 16 0 - 
A 231 0.4 88 0 0 0 0 0 0 0 3 9 0 0 0 S139 
G 319 0.0 0 0 100 0 0 0 0 0 0 0 0 0 0 - 
F 320 1.4 0 38 3 0 6 0 0 0 0 0 10 39 0 F241 
T 321 0.0 0 0 0 0 0 0 0 0 0 100 0 0 0 A242 
Y 322 0.6 12 1 3 0 0 0 0 0 0 0 1 83 0 T243 
R 416 0.9 0 0 0 8 0 0 0 69 0 1 0 0 21 A326 
 
Table 1.  
Amino-acid sequence entropy, H(x), and positional frequency at targeted  CV2025 
active-site residues.  
Values derived from 100 ωTAm sequences with at least 40% sequence identity to CV2025. 
Only amino acids with the highest positional frequency are shown. Residues in monomer A 
are underlined, the rest are in monomer B.  a "-" no equivalent residue in SPAT. Residue 
numbering for SPAT is from its UniProt accession number Q97VM5. 
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  Y153S Y153M WT 
Serine    
Km (mM) 13 (1) 4.6 (0.4) 260 (40) 
kcat (s
-1) 0.40 (0.01) 0.59 (0.01) 0.51 (0.05) 
kcat/Km (M
-1 s-1) 30 (3) 130 (10) 1.9 (0.3) 
rac-Aminoindane    
Km (mM) 0.43 (0.04) 10 (2.5) 15 (1) 
kcat (s
-1) 0.05 (0.001) 8.5 (0.8) 8 (1) 
kcat/Km (M
-1 s-1) 120 (13) 850 (200) 550 (90) 
(S)-MBA    
Km (mM) 8.7 (0.3) 11 (3) 28 (5) 
kcat (s
-1) 1.2 (0.1) 7.5 (0.5) 8 (1.7) 
kcat/Km (M
-1 s-1) 140 (10) 660 (200) 280 (80) 
 
Table 2. 
 Kinetic parameters for wild-type CV2025 transaminase and two mutants, Y153S and 
Y153M.   
Km is for the amine donor indicated in each case. Standard deviations are given in 
parentheses.  The aminoindane used was racemic. 
 
 
 
 
 
Schema 
 
 
 
Scheme 1 
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Figure 1.  
Structurally aligned active-sites of CV2025 ω-transaminase (blue) and the Sulfolobus 
solfataricus Serine:Pyruvate aminotransferase (SPAT) (grey).  
CV2025 ω-transaminase (PDB ID: 4A6U) (Humble et al. 2012) and SPAT (PDB ID: 3ZRP) 
(Sayer et al 2012) share 11% sequence identity, and aligned overall with DaliLite (Holm and 
Park 2000) to an RMSD of 3.4 Å.  Image A: Alignment of just one active-site, weighted on 
the PLP cofactor, is shown with active-site regions of CV2025 deviated significantly to 
SPAT, in red (region A), pink (region B), magenta (region C), and brown (region D).  PLP is 
shown as cyan sticks.  Image B: close up of W60, F88 and Y153 in CV2025 shown in sticks, 
with G9, F28 and F88 in SPAT shown in green sticks.  W60, F88 and Y153 (CV2025) align 
to G9, F28 and F88 (SPAT), respectively.  Images generated in Pymol (Delano 2002). 
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Figure 2.  
Phylogenetic analysis of transaminase structures.   
The sequences from 29 transaminase structures, refined by structure alignment, were used 
to construct a Neighbour-Joining tree.  PDB identifiers are shown on the tree.  The tree 
shown is aligned to the graph on the left which indicates the sequence identity (ID) and 
RMSD to CV2025 in each case. Also shown is the position (α-ω, n.d. = not determined) of 
the amine relative to the carboxylate moiety of the primary substrates associated with each 
structure, as annotated in the PDB and related literature.  Transaminases cluster primarily 
into αTAm and ωTAm clades. The αTAm clade can be split into two sub-clades in which 
structural region B is either similar to that in CV2025 or remodeled. SPAT is denoted as 
3ZRP. 
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Figure 3.  
Residues targeted for independent site-directed saturation mutagenesis.  
Each monomer forming the active site is coloured separately (green and grey). Target 
residues, and the pyridoxamine cofactor are highlighted in CPK sticks. Four of the 
substrates docked with AUTODOCK into holo-CV2025 (PDB ID: 4A6U), are also show in 
thick lines: MBA (green); acetophenone (light blue); serine (yellow); HPA (purple). Image 
generated in Pymol (Delano 2002). 
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Figure 4. 
Comparison of maximum activity improvements with the natural sequence entropies 
at active-site residues subjected to saturation mutagenesis. 
Maximum total activities relative to wild-type controls. Positional natural sequence entropies 
from an alignment of 100 ωTAm sequences with at least 40% identity to CV2025. The first 
seven sites are ordered by decreasing maximum activity, where mutants with activities 
higher than wild-type were identified.  For the remainder (Y168 onwards), maximum 
activities were from wild-type transformants as determined by DNA sequencing, and so 
these were plotted simply in order of H(x).  Error bars are standard deviations of the mean, 
except for uniquely sequenced mutants, for which a conservative standard error of 0.2 was 
assumed. Activities were measured in crude lysates towards 10 mM serine and 10 mM 
pyruvate, 0.2 mM PLP, in 0.1 M potassium phosphate, pH 7.0 at 37 °C. 
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Figure 5. 
  
Distribution of total activities for A) Y153X, B) W60X and C) F88X mutants, relative to 
wild-type.   
Error bars are standard deviations of the mean, except for uniquely sequenced mutants, for 
which a conservative standard error of 0.2 was assumed.  Activities were measured in crude 
lysates towards 10 mM serine and 10 mM pyruvate, 0.2 mM PLP, in 0.1 M potassium 
phosphate, pH 7.0 at 37 °C. 
 
